4.8 Review

Arterial hypertension

期刊

LANCET
卷 398, 期 10296, 页码 249-261

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(21)00221-X

关键词

-

资金

  1. Intramural Research Fund for the National Cerebral and Cardiovascular Center, Osaka, Japan [20-4-9]

向作者/读者索取更多资源

Arterial hypertension is a major contributor to the global burden of disease, but disease control remains poor. Diagnosis and treatment of hypertension should be based on a combination of various guidelines, with equal emphasis on pharmacological treatment and lifestyle adjustments. Device-based therapies such as renal denervation are rapidly evolving to expand therapeutic options.
Arterial hypertension is the most important contributor to the global burden of disease; however, disease control remains poor. Although the diagnosis of hypertension is still based on office blood pressure, confirmation with out-of-office blood pressure measurements (ie, ambulatory or home monitoring) is strongly recommended. The definition of hypertension differs throughout various guidelines, but the indications for antihypertensive therapy are relatively similar. Lifestyle adaptation is absolutely key in non-pharmacological treatment. Pharmacologically, angiotens-inconverting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, and diuretics are the first-line agents, with advice for the use of single-pill combination therapy by most guidelines. As a fourth-line agent, spironolactone should be considered. The rapidly evolving field of device-based therapy, especially renal denervation, will further broaden therapeutic options. Despite being a largely controllable condition, the actual rates of awareness, treatment, and control of hypertension are disappointingly low. Further improvements throughout the process of patient screening, diagnosis, treatment, and follow-up need to be urgently addressed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据